High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas
| Autor: | Ibrahim Güllü, Şuayib Yalçin, GÜLten Tekuzman, Ibrahim Barişlta, Necati Alkiş, Ismail Çelik, Nurullah Zengin, NilÜFer Güler, AyŞE Kars, EŞMen Baltali, Emin Kansu, DinÇEr Firat |
|---|---|
| Předmět: |
Adult
Male Cancer Research medicine.medical_treatment Pilot Projects chemistry.chemical_compound Refractory Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Ifosfamide Mesna Aged Chemotherapy business.industry Sarcoma General Medicine Middle Aged medicine.disease Nitrogen mustard Blood Cell Count Oncology chemistry Anesthesia Female business Progressive disease medicine.drug |
| Zdroj: | Scopus-Elsevier |
| Popis: | Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles. All patients had received prior doxorubicin- and cyclophosphamide-based chemotherapies. IF was administered at a dose of 3 g/m2 given as continuous intravenous infusion for 24 hr on day 1-5 with Mesna. In the absence of disease progression, chemotherapy was planned to be repeated every 4 weeks for six consecutive cycles. Following chemotherapy, only 2 patients (11%) achieved partial response with response durations of 6 and 9 months. There was no complete response. When considered for only high-grade tumors, the response rate reached up to 22%. Toxicity was reported for 48 cycles and the dose-limiting toxicities were myelosuppression (22%) and encephalopathy (17%). Chemotherapy protocol was changed after two or three courses in 16 patients with stable or progressive disease. IF/Mesna chemotherapy at this dose and schedule was not found to be very promising in refractory sarcomas as a second-line chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|